C - Chemistry – Metallurgy – 07 – H
Patent
C - Chemistry, Metallurgy
07
H
C07H 21/02 (2006.01) A61K 31/70 (2006.01) A61K 35/28 (2006.01) A61K 48/00 (2006.01) C12N 15/11 (2006.01)
Patent
CA 2150903
Ribozymes are provided in which the ribozymes have a catalytic sequence, two legs and at least one anchor sequence complementary to the substrate mRNA at a location that can be noncontiguous with the portions of the substrate mRNA complementary to the legs. In certain preferred embodiments, ribozymes capable of cleaving the L6 mRNA or both the L6 and K28 mRNAs are provided. Methods are provided for the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) patients having the L6 and K28 translocations and, therefore, the L6 mRNA. Additionally, combination treatments comprising components specific for both the K28 and L6 mRNAs are provided. Combination treatments are also provided for those patients which express c-myc in conbination with K28 and/or L6 mRNAs. Methods of treatment include, for example, administration of ribozymes and antisense olignucleotides directed against these mRNAs.
Coney Leslie R.
Oakes Fred T.
Pachuk Catherine J.
American Home Products Corporation
Borden Ladner Gervais Llp
LandOfFree
Compounds for the treatment of leukemias does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of leukemias, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of leukemias will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1816167